---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-26-001615"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2026-03-24T23:59:59+00:00"
generated_at: "2026-05-15T09:16:29.535850+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Silexion gets Israeli MoH approval for Phase 2/3 trial of SIL204 in pancreatic cancer

## Summary
- SIL204 is a next-generation RNAi therapy targeting multiple KRAS mutations in pancreatic cancer.
- Approval follows positive preclinical anti-tumor data and completed toxicology studies.
- Human trials expected to begin in Q2 2026; also planning German application in current quarter.
- Company plans to pursue additional KRAS-driven indications including colorectal and lung cancers.

## SEC filing metadata
- accession: 0001178913-26-001615
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2026-03-24T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891326001615/0001178913-26-001615-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891326001615/zk2634889.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-26-001615
- JSON: https://secwatch.observer/filing/0001178913-26-001615.json
- Plain text: https://secwatch.observer/filing/0001178913-26-001615.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.